Clinical trials: Aerosol Disease
Asthma Bronchiale, COPD
Investigation of the Respiratory Profile of Patients With Obstructive Pulmonary Disease (ASTHMA, COPD)
The primary aim of the OPTIPULM study is the evaluation of recorded pulmonary function curves and, based on them, the computer modelling of lung deposition for the individually used or potentially applicable inhalation drugs.
- Trial name
- OPTIPULM (NCT06966271)
- Where
- 7 sites in Hungary
- Volunteers
- 150 people
- Sponsor
- Tradeflex Ltd
Asthma
A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients
This is an open-label, randomized, cross-over, active-controlled study to evaluate the efficacy and safety effects using Meptin® Swinghaler and Berotec N® Metered Aerosol in stable asthma patients
- Trial name
- NCT01095016
- Testing
- Meptin swinghaler, Berotec
- Where
- Taiwan
- Volunteers
- 32 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
Respiratory Distress Syndrome (Neonatal), Intubation Complication
InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS
The purpose of this clinical study is to determine the effectiveness and safety of Infasurf® administered through the InfasurfAero™, a novel oral airway delivery device specifically designed to give Infasurf in a less complicated…
- Conditions
- Respiratory Distress Syndrome (Neonatal), Intubation Complication, Death; Neonatal
- Trial name
- Aero-05 (NCT05960929)
- Testing
- Infasurf Aero™
- Where
- 10 sites in United States
- Volunteers
- 220 people
- Sponsor
- ONY
Pulmonary Disease, Chronic Obstructive
Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study was to determine the pharmacokinetic comparability of 84 µg ipratropium bromide HFA-134a inhalation aerosol and 84 µg ATROVENT® CFC Inhalation Aerosol in COPD patients
- Trial name
- NCT02236169
- Testing
- Ipratropium bromide HFA-134a inhalation aerosol, Atrovent CFC inhalation aerosol
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
COVID-19
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of HH-120 for the Treatment of COVID-19
This is a randomized, double-blind, placebo-controlled Phase 1 study in participants over the age of 18 years with mild to moderate COVID-19.
- Trial name
- NCT06039163
- Testing
- HH-120
- Where
- 4 sites in China
- Volunteers
- 37 people
- Sponsor
- Huahui Health
Allergic Rhinitis
Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)
The purpose of this study is to compare the systemic des-ciclesonide exposure of OMNARIS™ (ciclesonide) nasal spray, ciclesonide HFA nasal aerosol, and orally inhaled ciclesonide HFA-metered-dose inhaler (MDI).
- Trial name
- NCT00458835
- Testing
- Ciclesonide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Covis Pharma S.à.r.l.
Oral Mucositis
Polyphenol Rich Aerosol as a Support for Cancer Patients in Minimizing Side Effects After a Radiation Therapy
The aim of the study is to demonstrate in a clinical condition the effectiveness of a preparation that is a mixture of plant extracts rich in polyphenolic compounds in the aspect of supporting cancer patients in minimizing side…
- Trial name
- NCT05994638
- Testing
- Aerosol (Polyphenol-rich plant extracts, Hyaluronic Acid, Cetraria Islandica, Vitamin B3)
- Where
- Poland
- Volunteers
- 10 people
- Sponsor
- AronPharma Sp. z o. o.
Chronic Obstructive Pulmonary Disease
PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The overall objective of this study is to determine an optimal dose and dosing regimen of PT001 MDI for further evaluation in later stage studies.
- Trial name
- NCT01350128
- Testing
- PT001 MDI, Ipratropium Bromide HFA Inhalation Aerosol
- Where
- 8 sites in United States
- Volunteers
- 103 people
- Sponsor
- Pearl Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease
The objective of this study is to confirm that chronic dosing of 20 mcg and 40 mcg of ipratropium bromide, administered via the RESPIMAT device, demonstrates clinical comparability and similar safety profiles to the 36 mcg dose…
- Trial name
- NCT02177344
- Testing
- Low dose of Ipratropium bromide, High dose of Ipratropium bromide, Atrovent
- Volunteers
- 646 people
- Sponsor
- Boehringer Ingelheim
Perennial Allergic Rhinitis
Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray
This is a randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate patient preference, satisfaction and efficacy of ciclesonide nasal aerosol versus…
- Trial name
- NCT01401465
- Testing
- ciclesonide, mometasone
- Where
- 15 sites in United States
- Volunteers
- 327 people
- Sponsor
- Sumitomo Pharma America, Inc.
Asthma
Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
Study to assess the efficacy and safety of four doses of budesonide inhalation aerosol (BD MDI, PT008) relative to placebo MDI in adult subjects with mild to moderate persistent asthma.
- Trial name
- NCT02105012
- Testing
- BD MDI 320 µg, BD MDI 160 µg, BD MDI 80 µg
- Where
- 41 sites in United States
- Volunteers
- 147 people
- Sponsor
- Pearl Therapeutics, Inc.
Bronchial Asthma
Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INH
To compare the therapeutic equivalence of Beclomethasone Dipropionate MDI (Inhalation Aerosol) 0.04 mg/ INH with the marketed QVAR® 40 mcg (Beclomethasone dipropionate hydrofluoroalkane (HFA)) and to demonstrate superiority of…
- Trial name
- QVR (NCT04051710)
- Testing
- Test Product, Reference Product
- Where
- India
- Volunteers
- 1,550 people
- Sponsor
- Aurobindo Pharma Ltd
Skin and Connective Tissue Diseases
A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris
The purpose of this study is to evaluate the anti-psoriatic effect of LEO 90100 aerosol foam compared with Betesil® medicated plaster
- Trial name
- NCT02518048
- Testing
- LEO 90100 Aerosol foam, Betesil® 2.25 mg
- Where
- France
- Volunteers
- 35 people
- Sponsor
- LEO Pharma
Pulmonary Disease, Chronic Obstructive
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotro pium HandiHaler® 18 mcg daily compared to Combivent® MDI CFC Inhalation Aerosol 2 actuations qid in COPD patients currently…
- Trial name
- NCT00388882
- Testing
- tiotropium, ipratropium bromide / albuterol
- Where
- 40 sites in United States, Argentina and 3 more
- Volunteers
- 327 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Pulmonary
Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension
The aim of this study is to monitor long-term safety and tolerability of iloprost aerosol inhalation therapy in patients suffering from pulmonary hypertension.
- Trial name
- NCT00185315
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Where
- 16 sites in Belgium, France and 5 more
- Volunteers
- 71 people
- Sponsor
- Bayer
Bronchial Asthma
BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma
The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product, using bronchoprovocation (methacholine challenge testing) in adult patients with stable mild asthma.
- Trial name
- NCT06154304
- Testing
- Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation), Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1, Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Cipla Ltd.
HIV Infections
The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS
To determine safety and tolerance of administering aerosolized recombinant interferon gamma (IFN-gamma) for 4 weeks in patients with AIDS. To examine activation of alveolar macrophages by aerosolized IFN-gamma administration.
- Trial name
- NCT00002433
- Testing
- Interferon gamma-1b
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Amgen
Asthma
A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)
To Evaluate the Pharmacodynamic Equivalence of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg base (Sun Pharmaceuticals Industries Limited) to PROAIR® HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg base (Teva Respiratory…
- Trial name
- NCT03528577
- Testing
- Zero-dose, 90 mcg of PROAIR® HFA, 180 mcg of 90 mcg of PROAIR® HFA
- Where
- 8 sites in United States
- Volunteers
- 128 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Perennial Allergic Rhinitis, PAR
Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, safety study of the effects of ciclesonide nasal aerosol (74 mcg) on the HPA axis when administered once daily to male and premenarchal female…
- Trial name
- NCT01378429
- Testing
- ciclesonide nasal aerosol
- Where
- 7 sites in United States
- Volunteers
- 89 people
- Sponsor
- Sumitomo Pharma America, Inc.
Seasonal Allergic Rhinitis
Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis
To demonstrate the efficacy of ciclesonide HFA applied as a nasal aerosol (160 μg and 80 μg) once daily compared to placebo in subjects with SAR.
- Trial name
- NCT00790023
- Testing
- 80 mcg Ciclesonide, 160 mcg Ciclesonide
- Where
- 4 sites in United States
- Volunteers
- 707 people
- Sponsor
- Sumitomo Pharma America, Inc.